Market News & Trends
Zafgen Announces Positive Results for Phase 2 Clinical Trial
Zafgen, Inc. recently announced positive data for the second cohort of its Phase 2 clinical trial of ZGN-1061, designed to evaluate efficacy and safety in…
TrakCel & Quick Partner to Provide Industry-Leading Digital Supply Chain IT Solution for Cell & Gene Therapies
TrakCel and The Quick Life Science Group recently announced a partnership to offer an integrated IT logistics orchestration platform.
MilliporeSigma & Roche Renew Global Distribution Agreement
MilliporeSigma and Roche recently announced they have agreed to renew their current distribution agreement for the Biochemical Reagents and Kapa Biosystems product portfolios, as well as select qPCR & Nucleic Acid Purification products.
Bavarian Nordic Announces Exercise of $44-Million Option by BARDA
Bavarian Nordic A/S recently announced the US Biomedical Advanced Research and Development Authority (BARDA) have exercised another option under the ongoing contract for freeze-dried MVA-BN smallpox vaccine.
Lonza & Takeda Partner in Development & Manufacture of Cancer Treatment
Lonza recently announced another major milestone in its multiproduct partnership with Takeda.
Immutep Enters Into Clinical Trial Collaboration, Service, and Supply Agreement
Immutep Limited recently announce it has entered into a clinical trial collaboration agreement, a supply agreement, and a service agreement with CYTLIMIC Inc. for its…
Sublimity Therapeutics Receives IND Clearance
Sublimity Therapeutics recently announced that the company has received FDA clearance to proceed with its Phase 2b clinical trial of the company’s lead drug candidate,…
BioTime Enters Into Exclusive Agreement With Orbit Biomedical
BioTime, Inc. recently announced it has entered into a research and option agreement with Orbit Biomedical Limited. Orbit Biomedical, based in London, UK, and Ambler, PA,…
Lilly Announces Agreement to Acquire Loxo Oncology
Eli Lilly and Company and Loxo Oncology, Inc. recently announced a definitive agreement for Lilly to acquire Loxo Oncology for $235 per share in cash,…
Athenex Announces Completion of Target Enrollment in Phase III Study
Athenex, Inc. recently announced that target enrollment of 360 patients in the Oraxol Phase III clinical trial in metastatic breast cancer has been achieved on…
Vital Therapies & Immunic Therapeutics Announce Transaction to Create Leading Company
Vital Therapies, Inc. and Immunic AG recently announced they have entered into a definitive agreement under which Vital Therapies is expected to acquire all of the…
MedPharm Announces Expansion of US Center of Excellence
MedPharm Ltd recently announced the expansion of its US Center of Excellence in Durham, NC, in response to increasing service demand for its topical and transdermal formulation development and performance testing services.
PCI Pharma Services Announces $20-Million Expansion of Biotech Technologies, Including Advanced Injectable Delivery Forms
Leading global biopharmaceutical services provider PCI Pharma Services (PCI) has announced a momentous investment in support of biologic medicines and advanced injectable delivery forms, totaling more than $20 million.
Catalent Makes Significant Investment to Expand Biologics Capacity & Capabilities
Catalent, Inc. recently announced it has commenced a $200 million capital investment in its Biologics business to expand drug substance manufacturing capacity and drug product fill/finish capacity due to projected growth among existing and future customers.
Bristol-Myers Squibb’s Acquisition of Celgene Could Position Company Amongst Top Five Most Profitable Pharma Giants
Following Bristol-Myers Squibb’s (BMS) announcement that it will acquire Celgene in a cash and stock deal with an equity value of approximately $74 billion, Edit…
Elite Pharmaceuticals & SunGen Pharma File ANDA
Elite Pharmaceuticals, Inc. recently announced it filed an Abbreviated New Drug Application (ANDA) with the US FDA for a generic version of an antibiotic product. This…
Sarepta Therapeutics Enters Strategic Relationship With Aldevron
Sarepta Therapeutics, Inc. and Aldevron recently announced they have entered into a long-term strategic relationship for the supply of plasmid DNA to fulfill Sarepta’s needs…
Acer Therapeutics Announces Exclusive License Agreement With Sanofi
Acer Therapeutics Inc. recently announced it has entered into an exclusive license agreement with Sanofi to acquire worldwide rights to osanetant, a clinical-stage, selective, non-peptide…
Merus Announces Strategic Collaboration With Betta Pharmaceuticals
Merus N.V. recently announced it has agreed to grant Betta Pharmaceuticals Co Ltd an exclusive license to develop and commercialize Merus Biclonics MCLA-129 in China. …
Allena Pharmaceuticals Achieves Alignment With FDA on Phase 3 Program
Allena Pharmaceuticals, Inc. recently announced it has reached alignment with the US FDA on both the design of URIROX-2, its second pivotal Phase 3 trial…
